Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : The Benchmark Company, LLC
Deal Size : $4.5 million
Deal Type : Financing
Alpha Cognition Completes $4.5M Convertible Note and Bridge Financing
Details : The proceeds from the financing will be utilized to continue commercialization work for the Company’s recently approved Zunveyl (benzgalantamine), indicated for the treatment of Alzheimer's disease.
Brand Name : Zunveyl
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 24, 2024
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : The Benchmark Company, LLC
Deal Size : $4.5 million
Deal Type : Financing
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease
Details : ZUNVEYL, a prodrug of AD treatment galantamine and an acetylcholinesterase inhibitor (AChEI), is postulated to exert its therapeutic effect by preventing the breakdown of acetylcholine.
Brand Name : Zunveyl
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 29, 2024
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $6.5 million
Deal Type : Public Offering
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering
Details : The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Brand Name : ALPHA-1062
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 22, 2023
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $6.5 million
Deal Type : Public Offering
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ALPHA-1062 (benzgalantamine), AChE inhibitor delayed-release oral tablet formulation. Currently being evaluated in the Phase III clinical trial studies for the treatment of mild-to-moderate Alzheimer’s Disease.
Brand Name : ALPHA-1062
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 07, 2023
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $6.5 million
Deal Type : Private Placement
Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering
Details : The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Brand Name : ALPHA-1062
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 04, 2023
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $6.5 million
Deal Type : Private Placement
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Spartan Capital Securities
Deal Size : $6.5 million
Deal Type : Private Placement
Alpha Cognition Announces Third Closing of Private Placement and Continuation of the Offering
Details : The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Brand Name : ALPHA-1062
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 08, 2023
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Spartan Capital Securities
Deal Size : $6.5 million
Deal Type : Private Placement
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $97.8 million
Deal Type : Private Placement
Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering
Details : The Company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Brand Name : ALPHA-1062
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 16, 2023
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $97.8 million
Deal Type : Private Placement
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ALPHA-1062, a proprietary, patented, delayed release oral tablet formulation in development for the treatment of mild-to-moderate Alzheimer’s Disease.
Brand Name : ALPHA-1062
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 27, 2023
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $1.3 million
Deal Type : Private Placement
Details : The Company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Brand Name : ALPHA-1062
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 31, 2023
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $1.3 million
Deal Type : Private Placement
Lead Product(s) : Galantamine Prodrug
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : AMRMC
Deal Size : $0.7 million
Deal Type : Funding
Details : The funds will support preclinical study of ALPHA-1062, an inactive galantamine prodrug and a new generation acetylcholinesterase inhibitor being developed for Alzheimer’s disease, to reduce blast mild Traumatic Brain Injury induced functional deficit ...
Brand Name : ALPHA-1062
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 07, 2023
Lead Product(s) : Galantamine Prodrug
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : AMRMC
Deal Size : $0.7 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?